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The most characteristic feature of neuroﬁbromatosis type 1 (NF1) is the development of neuroﬁbromas. It has been suggested
that these tumors are caused by somatic inactivation of the wild-type NF1 allele, but the cell that originally suﬀers this mutation
remains controversial. Several lines of evidence support the clonal origin of these tumors, and it has been recently suggested
that skin-derived precursor cells (SKPs) could be the cell of origin of dermal neuroﬁbromas. Nullizygous (NF1−/−)S K P sd o
give rise to neuroﬁbromas when transplanted to heterozygous mice. Moreover, a nullizygous population of cells that is S100β
negative is present in human neuroﬁbromas, and NF1+/− multipotent progenitor cells are seemingly recruited to the tumor. This
evidence supports the neuroﬁbroma stem cell hypothesis and a putative involvement of SKPs in the aetiopathogenesis of the
disease, suggesting that SKPs could become a valuable tool for the in vitro study of NF1.
1.Introduction
The tumor predisposition disorder von Recklinghausen’s
neuroﬁbromatosis type I (NF1) is one of the most common
genetic disorders of the nervous system, aﬀecting 1 in
3500 individuals worldwide [1–4]. The disease is caused by
mutation in the NF1 gene (located on chromosome 17q11.2)
that encodes the tumor suppressor protein neuroﬁbromin, a
GTPase-activating protein (GAP) [5, 6].
Neuroﬁbromasarecomplextumorsthatcontainprolifer-
ating Schwann-like cells and other local supporting elements
of the nerve ﬁbers, as perineurial-like cells, ﬁbroblasts,
endothelialcells,pericytes,andvascularsmoothmusclecells,
as well as inﬁltration of mast cells [7]. Although several
reports have studied which cell originates this tumor, the
present data are somewhat contradictory. In this paper
we will address the issue of the cell of origin for dermal
neuroﬁbromas to explore if the available data support the
cancerstemcellhypothesis.Wewilldiscussrecentﬁndingsin
thelightofpossibleinvolvementoftheso-calledskin-derived
precursor cells in the aetiopathogenesis of this complex
disease.
2.Skin-DerivedPrecursors(SKPs)
Skin-derived precursors (SKPs) are a population of neural
crest-derived multipotent precursor cells present in both
human and mouse dermis. They can be identiﬁed in vitro as
nonadherent cells isolated from the dermis that proliferate
a n ds e l f - r e n e wi nr e s p o n s et og r o w t hf a c t o r sF G F - 2a n d
EGF. Under speciﬁc diﬀerentiation conditions, they give rise
to progeny of the neuronal, glial, and mesodermal lineages
[8–14].
SKPs thus derive from the dermis and apparently are
distinct from mesenchymal stem cells and from central
nervous system neural stem cells [8, 13], although they
express genes characteristic of embryonic neural crest cells,
such as Slug, Snail, Twist, Pax3, and Sox9 [8].
In vitro, SKPs can be diﬀerentiated into mesodermal
lineages such as SMA+ smooth muscle cells and adipocytes,
as well as into neural crest-derived tissues such as neurons
andSchwanncells[8,13].Inparticular,SKPsgiverisetocells
with neuronal morphology that express the pan-neuronal
markers βIII tubulin and neuroﬁlament-M and proteins
characteristic of peripheral neurons such as p75NTR,2 Stem Cells International
peripherin, NCAM, tyrosine hydroxylase, and dopamine β-
hydroxylase. SKPs can also be diﬀerentiated into bipolar cells
coexpressing glial ﬁbrillary acidic protein GFAP, CNPase,
S100β, and p75NTR, typical markers of cells with a diﬀeren-
tiated Schwann phenotype, as well as MBP and P0 peripheral
myelin protein [8, 13].
When transplanted in ovo into the chick neural crest
migratory stream, SKPs mostly migrated into peripheral
neural crest targets such as spinal nerve, dorsal root ganglia,
andskinandexpressedS100β[8].Invivo,ithasrecentlybeen
reported that SKPs derive from Sox2+ follicle-associated
dermal precursors and show characteristics of dermal stem
cells. In this respect, they contribute to dermal maintenance,
wound healing, and hair follicle morphogenesis [15].
3. Type 1 Neuroﬁbromatosis (NF1)
The primary clinical feature of NF1 is the development of
benign peripheral nerve sheath tumors, termed neuroﬁbro-
mas [16]. In a small percentage of NF1 patients, a particular
type of neuroﬁbromas (plexiform, see below) progress
to malignant peripheral nerve sheath tumors (MPNSTs).
NF1 patients are also predisposed to astrocytic brain tu-
mors, pheochromocytoma, and juvenile myelomonocytic
leukaemia [2, 17]. Noncancerous symptoms of the disease
may include intellectual deﬁcits, bone deformations, benign
lesions of the iris (Lisch nodules), axillary freckling, and
hyperpigmentation defects of the skin known as caf´ e-au-lait
macules. Because many of the cardinal features of the disease
aﬀect neural crest-derived tissues, NF1 is considered as a
neurocristopathy [16, 18–20].
NF1 is a dominantly inherited genetic disease. Half of
the NF1 patients have inherited their NF1 mutation and the
other half are caused by a de novo NF1 mutation, suggesting
that the NF1 locus may represent a mutational hotspot in the
human genome [3, 4, 16, 21]. Neuroﬁbromin, the NF1 gene
product, has a Ras GTPase activating (RasGAP) activity and
negatively regulates Ras signaling [22, 23]. Neuroﬁbromin
functions as a tumor suppressor protein expressed in many
cells although it is more abundant in cells from the nervous
system such as neurons, Schwann cells, astrocytes, and
oligodendrocytes as well as in leukocytes [6, 24, 25]. Loss or
reduced neuroﬁbromin expression leads to an increased Ras
activityandithasbeenassociatedwithincreasedmammalian
target of rapamycin (mTOR) activity in astrocytes and
Schwann cells [26, 27]. Moreover, neuroﬁbromin plays a
key role in the generation of cyclic AMP (cAMP) in both
neurons and astrocytes [28, 29]. Loss of heterozygosity
(LOH) in the inherited wild-type allele has been detected
in some tumor types in NF1 patients, although it has been
demonstrated that heterozygosity for NF1 is a key element
for the development of many NF1 symptoms, including
neuroﬁbroma formation [30]. An additional complexity of
the disease is its variable phenotypic expression, suggesting
that modiﬁer genes and epigenetic phenomena may play an
important role in disease manifestations [2].
4. Neuroﬁbroma Subtypes and
Cellular Components
The most common and complex feature of NF1 is the
development of benign peripheral nerve sheath tumors or
neuroﬁbromas. Neuroﬁbromas were classiﬁed by WHO into
ﬁ v es u btype s[ 31]: localized cutaneous, localized intraneural,
plexiform, diﬀuse cutaneous, and soft tissue diﬀuse neuroﬁ-
bromas (elefantiasis neuromatosa).
Cutaneous neuroﬁbromas reside exclusively in the skin
and occur in virtually all individuals with NF1. They initially
appear at puberty and increase in number with age and
during pregnancy, suggesting a hormonal component in
disease development [32–35]. These benign tumors, ranging
from 0.1 to several cm in diameter, grow as discrete lesions in
the dermis. Patients sometimes develop thousands of these
tumors. Depending on their location, they can be painful
and disﬁguring for the patient and thus aﬀect their quality of
life. In contrast, plexiform neuroﬁbromas develop internally
along the plexus of major peripheral nerves and become
quite large, sometimes involving an entire limb or body
region [36]. They occur in about 30% of the individuals and
are thought to be congenital. While these tumors are also
benign, they are debilitating and may progress to malignancy
[37, 38]. The cellular make-up of these lesions is generally
similar to that of dermal lesions.
In a physiological situation, a single peripheral nerve
shaft is associated with myelinating or nonmyelinating
Schwann cells. Several nerve ﬁbers and associated Schwann
cells are clustered into a nerve fascicle, each fascicle being
surrounded by concentric layers of perineurial cells. Fibrob-
lasts, endothelial cells, and occasional mast cells are also
present in a normal nerve fascicle (Figure 1)[ 7, 16, 37,
38]. Neuroﬁbromas contain all of the cell types found in
normal peripheral nerve but in inappropriate numbers.
Moreover, Schwann cells are found dissociated from nerves
and the perineurium is often disrupted. Large amounts of
intercellular collagen and ground substance are also typically
present in neuroﬁbromas [16].
5.How Many Mutagenic Events Are Needed for
Neuroﬁbromas to Arise?
The penetrance of NF1 is 100% by age 20, although the
degree of severity is highly variable, even among family
members that present the same mutation [1, 39].
Two types of congenital NF1 mutations have been found
to inﬂuence neuroﬁbroma number [40–42]. However, these
two types of mutations aﬀect only a small percentage of NF1
patients, and, moreover, patients bearing the same germline
mutation can exhibit a very diﬀerent number of dermal
neuroﬁbromas [43, 44], indicating that other mechanisms
are implicated in neuroﬁbroma formation.
Somatic mutations in the NF1 gene have been found
in tumors associated with NF1, leading to functional loss
of both alleles of the gene [45–47]. For example, loss of
heterozygosity (LOH) in chromaﬃn cells initiates pheochro-
mocytomas, and LOH in melanocytes produces pigmentedStem Cells International 3
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Figure 1: Cellular organization of a normal nerve shaft and a neuroﬁbroma. (a) Nerve shafts are made up of axons and associated Schwann
cells. Endoneurium is connective tissue composed by collagen, ﬁbroblasts, mast cells, capillaries and extracellular matrix. Collagen ﬁbers are
tighter and more compact near the perineurium. The perineurium is composed by ﬂattened ﬁbroblasts, collagen and elastic ﬁbres. (b) In
a neuroﬁbroma, the cells are the same as in a normal nerve shaft, but increased in number. There are more Schwann cells and they can be
dissociated from axons. Two kinds of Schwann cells can be detected: NF1+/− and NF1−/−. Fibroblasts and mast cells are also increased in
number but they are all heterozygous (NF1+/−). The collagen deposits are also increased and perineurium is usually disrupted.
lesions such as caf´ e-au-lait macules and Lisch nodules. LOH
in myeloid cells induces myelomonocytic leukaemia, and
LOH in glial cells permits astrocytoma formation [48–53].
It has also been suggested that neuroﬁbromas are caused
bysomaticinactivationofthewild-typeNF1allele,leadingto
completefunctionalabrogationofthegene[45,54,55].LOH
inSchwannprogenitorcellspermitsplexiformneuroﬁbroma
formation [30, 56], and it has been suggested that LOH
in skin-derived precursors leads to cutaneous neuroﬁbroma
formation [34]. Using both NF1 intragenic polymorphisms
and markers from ﬂanking and more distal regions of
chromosome 17, Colman et al. demonstrated loss of het-
erozygosity (LOH) of the NF1 gene in eight neuroﬁbromas
from 22 patients and Serra et al. found LOH in 15 out of
60 dermal neuroﬁbromas [55, 57]. Moreover, Sawada et al.
identiﬁed a somatic deletion of the NF1 gene in a dermal
neuroﬁbroma with a deﬁned germline mutation [54]. LOH
has also been detected in plexiform neuroﬁbromas [58–60].
One possible explanation for the lack of allele loss detec-
tioninsome tumorsis thatamoresubtlesomatic NF1muta-
tion occurred (point mutation, small deletion, insertion,
or modiﬁcation through epigenetic mechanisms). These
changes do not produce loss of closely linked polymorphic
marker loci [61]. Alternatively, LOH may stay undetected
because the presence of normal stromal or inﬂammatory
tissue within the tumors increases sample background. Nev-
ertheless, mechanisms that do not involve inactivation of the
normal allele cannot be excluded. In dermal neuroﬁbromas,
localtraumacanbeafactorinthedevelopmentofthetumors
[62] and it has been suggested that dermal neuroﬁbromas
could be hyperplastic instead of neoplastic lesions, due to
a poorly regulated wound healing in NF1 haploinsuﬃcient
tissues [63–65]. However most experts agree that these
lesions are true neoplasms and are not hyperplastic.
6. Which Neuroﬁbroma Cells Harbor Somatic
NF1 Mutations?
Being a complex genetic disease with tumors of multicellular
composition, the question arises which cell type within
the tumor presents the secondary somatic mutations that
characterize the pathological presentation of the dermal
neuroﬁbromas. Although NF1−/−ﬁbroblasts exhibit greater
proliferation capacity than their normal and heterozygous
counterparts[63,66],theyarenotnormallyfoundintumors
since only Schwann cells carry a double inactivation of the
NF1 gene [59, 61, 67–69].
Two diﬀerent populations of S100β+ cells (presumably
terminally diﬀerentiated Schwann cells) have been demon-
strated within in vitro cultures obtained from dermal neu-
roﬁbromas, indicating that both NF1 Schwann cell subtypes
(+/−)a n d( −/−) coexist in these tumors [61, 68]. This fact
maybeexplainedthroughtwoalternativepossibilities:(i)the4 Stem Cells International
second hit mutation occurred as a secondary event within a
neuroﬁbroma that had already developed polyclonally, and
thus only a subpopulation of S100β+ cells is (−/−), or (ii)
the tumors arose through a two-hit mechanism within a
stem/progenitor cell that gave rise to most tumor cells, but
theproliferatingneoplasticclonestimulatedtheproliferation
of inﬁltrating nonneoplastic cells such as heterozygous
Schwann cells, mast cells, and ﬁbroblasts.
The inﬂuence of a heterozygous environment in plex-
iform neuroﬁbroma development supports the latter the-
ory. In a conditional plexiform neuroﬁbroma mice model
(NF1ﬂox/−; Krox20cre), haploinsuﬃcient stromal and mast
cells (NF1+/−) are necessary and limiting for neuroﬁbroma
development [30, 70]. Accordingly, NF1−/− Schwann cell-
derived secreted stem cell factor (SCF) causes a hyperactive
recruitment of NF1+/− mast cells [71]. Furthermore, NF1
mast cells secreted 2.5-fold higher TGFβ than wt mast cells,
leading to a heightened ﬁbroblast proliferation, migration,
and collagen production [72]. In all, these data reinforce the
idea that heterozygous ﬁbroblast and mast cells may play a
key role in the neuroﬁbroma pathogenesis [70].
7. Does Neuroﬁbroma Originate from
Stem/Progenitor Cells?
Cancer is a heterogeneous disease and tumors present a
signiﬁcant morphological, phenotypic, genetic, kinetic, and
functional diversity. Several lines of evidence suggest that
this heterogeneity could be due to a hierarchical organiza-
tion of tumors that resembles normal tissue development.
However another possible explanation is that tumor cells
are biologically equivalent and that heterogeneity derives
from extrinsic or intrinsic inﬂuences that result in stochastic
responses [73]. Strong evidence points to the importance
of stem cells in the initiation and long-term maintenance
of several cancers, as malignant germ cell cancers [74, 75],
leukemias [76, 77], nervous system [78], breast [79]a n d
colon cancers [80–83]. In these cancer types, several markers
have been identiﬁed to distinguish the so called “cancer
stem cells” that may form tumors when serially transplanted
intoimmunocompromisedNOD/SCIDmiceascomparedto
nontumorigenic cancer cells that do not present self-renewal
capacities. Nevertheless, it is worth noting that in some
cancers, most tumor cells fulﬁll this tumorigenic potential
[84–86] and that the NOD/scid mouse transplantation assay
sometimes might underestimate the frequency of human
cancer cells with tumorigenic potential [85, 86].
The two-hit tumor suppressor hypothesis for NF1
predicts that all cells carry a constitutional mutation and
a particular cell acquires a second mutation to initiate
tumor formation [87]. Based on the two-hit model of
tumorigenesis, tumor cells in neuroﬁbromas should be of
clonal origin. Nevertheless, while both alleles are inactivated
in NF1-associated malignancies, the clonal nature of the
neuroﬁbromas is controversial (see below) [58, 67, 88–91].
Interestingly, there is strong evidence that an adult mul-
tipotent stem/progenitor cell could be the cell of origin for
cutaneous neuroﬁbromas. It has been demonstrated that
plexiform neuroﬁbromas originate from embryonic neural
crest-derived progenitors [30, 56, 92–96] and mice that
develop plexiform tumors with 100% frequency fail to
develop dermal tumors. Moreover, plexiform neuroﬁbromas
are congenital while cutaneous neuroﬁbromas arise in
puberty. The facts that dermal neuroﬁbromas arise in the
adulthood and locate in the dermis suggest the idea that
dermal adult progenitor cells could be the source of these
tumors [34]. Furthermore, the close relationship observed
between the development of cutaneous neuroﬁbromas and
hair follicle proximity suggests that adult progenitor cells
residing in the hair follicle may be the origin of these
tumors. There is evidence that the neuroﬁbromas arise
in the hair follicle vicinity and even small neuroﬁbromas
can be detected histologically in close contact with the
hair follicle, in otherwise apparently healthy skin areas [97,
98]. Mechanical trauma has also been suggested to play a
role in the pathogenesis of neuroﬁbromas, that is, some
neuroﬁbromas appear to arise as a dysplastic response to
crush trauma [99].
Several populations of stem/progenitor cells have been
described to reside in the hair follicle or surrounding areas
[81, 100–114], some of them being potential candidates for
an involvement in NF1 pathogenesis. Recently, it has been
speculated that recruitment of Nestin+ multipotent NF1+/−
precursor cells is associated with cutaneous neuroﬁbroma
development[97].Histologically,nestin-positivesmallblood
vessels and spindle-shaped tumor cells can be detected
in the neuroﬁbromas. In accordance with this hypothesis,
S100β−/NF1− cells are detected in high proportion (16–
31%) in neuroﬁbromas. This fact could indicate the presence
of multipotent stem cells that have suﬀered a second-hit
mutation, although a dediﬀerentiation from S100β+/NF1−
Schwann cells, also present in the tumor, can not be excluded
[91].
Finally, there is strong evidence that SKPs could be the
cell of origin for dermal neuroﬁbromas [34]. Cre-mediated
recombination of NF1lox/− SKPs induced in vitro loss of
the wt allele in these cells. When transplanted into the
same NF1lox/− mice that originated these cells, NF1−/−
SKPs (but not control NF1lox/− cells) then initiated dermal
neuroﬁbromas.However,tumorformationwasonlyeﬃcient
infemalerecipientsthatwerepregnantatthetimeofimplan-
tation, highlighting the hormone sensitivity observed in
NF1 patients and the importance of the microenvironment
during neuroﬁbroma formation. Furthermore, deletion of
NF1 in the skin of CMV-CreERt2 NF1lox/− mice after topical
application of tamoxifen led to local dermal neuroﬁbroma
formation, supporting the notion that the cell of origin for
these tumors resides within the skin at close range of topical
tamoxifen application [34, 115].
8. SKPs as a Tool for In Vitro Modelling of
NF1 Features
Several lines of evidence now point to a stem cell origin of
dermalneuroﬁbromas.Ontheonehand,anumberofstudies
have assessed the clonal origin of neuroﬁbromas, based onStem Cells International 5
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Figure 2:IsolationofSKPsfromhealthyskinandaneuroﬁbromaofanNF1patient.(a)Dermalmultipotentstemcellsformspheresinvitro,
in response to EGF and FGF. In NF1 patients, SKPs from healthy skin should give rise to NF1+/− SKPs in vitro (a1). SKPs can diﬀerentiate
into glial, neuronal, and mesodermal lineages. If SKPs are isolated from NF1 patient neuroﬁbromas, NF1+/− SKPs (b1) are expected to form
in vitro, under standard culture conditions. If NF1−/− (b2) SKPs may be isolated has to be determined. If SKPs are the cell of origin of
neuroﬁbromas, they might present a predisposition to diﬀerentiate into the glial lineage.
X chromosome inactivation (XCI) clonality assay. In our
view, the results are still controversial since (i) clonal cell
origin may not formally be proven through XCI analyses
and (ii) studies have generally been performed with low
patient numbers. For instance, Skuse et al. studied eight
dermal neuroﬁbromas and concluded that all of them were
of clonal origin [90]. Tucker et al. also found evidence for
clonality in some of the six neuroﬁbromas studied [91],
suggestingthatalthoughothermechanismscouldbeatstake,
at least in some neuroﬁbromas a unique stem cell may have
suﬀered a second-hit mutation, giving rise to a nullizygous
Schwann cell progeny. On the other hand, only one kind
of somatic mutation has been found in every neuroﬁbroma
analyzed and diﬀerent neuroﬁbromas of the same patient
present diﬀerent somatic mutations [61, 68], reinforcing the
neuroﬁbroma stem cell hypothesis. Moreover, multipotent
stem cells (termed neuroﬁbroma-derived precursor cells or
NFPs) have been isolated from dermal neuroﬁbromas. These
precursors express Nestin and show a multipotent diﬀer-
entiation potential, giving rise to Schwann cells, neurons,
epithelial cells, and adipocites [97]. However NFPs do not
contain the somatic NF1 mutation and thus their relation-
ship with NF1 pathogenesis is currently unclear. Similarly,
characterization of cells present in neuroﬁbromas by S100β,
a marker for the Schwann lineage, has demonstrated that a
nullizygous population (NF1−/−) that is negative for S100β
expression is present in neuroﬁbromas. Although it cannot
be discarded that they could be dediﬀerentiated Schwann
cells, it is also possible that they could be progenitor cells
that have suﬀered the somatic mutation and that generate
the Schwann cells present in the tumor. In any case, cell
characterization by a single marker is less than optimal and
too many interpretations of these results are possible as to
extract any meaningful conclusion.
Recently, an elegant study showed that NF1+/− SKPs
could form neuroﬁbromas in a conditional mouse model,6 Stem Cells International
although a key role for tumor environment was also found
[34]. To date there is no data on involvement of SKPs in
human neuroﬁbroma development, although NF1+/− mul-
tipotent progenitor cells are supposedly recruited to form
dermal neuroﬁbromas [97]. If SKPs were the cells of origin
of dermal neuroﬁbromas, NF1−/− SKPs should be present
within NF1 patient neuroﬁbromas, although NF1+/− SKPs
should also be detected. If these putative NF1−/− SKPs would
present a predisposition to diﬀerentiate preferentially into
the Schwann cell lineage should also be explored (Figure 2).
9. Conclusions
In summary, current evidence supports the notion that, at
least in murine models, skin-derived precursor cells (SKPs)
might be a cell of origin for dermal neuroﬁbromas. It is
also conceivable that human SKPs might be the cell of
origin of neuroﬁbromas, although formal proof for this is
lacking. Isolation of SKPs from human neuroﬁbromas could
demonstrate if these dermal multipotent stem cells bear the
somaticmutationandwhetherornotthismutationconfersa
predispositiontotheseprecursorcellstodiﬀerentiateintothe
Schwann cell lineage. Furthermore, isolation of SKPs from
healthy skin of NF1 patients could demonstrate if there are
SKPs with the somatic mutation, even in areas where the
neuroﬁbroma is histologically undetectable. In conclusion,
SKPs may become a useful tool for the in vitro study of the
neuroﬁbromatosis type 1 syndrome.
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